Corinne Jenkins
Stock Analyst at Goldman Sachs
(2.29)
# 1,462
Out of 4,667 analysts
66
Total ratings
45.45%
Success rate
-1.66%
Average return
Main Sectors:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $31.15 | -29.37% | 8 | Nov 5, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $77 → $74 | $85.64 | -13.59% | 5 | Aug 8, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $2.99 | +401.67% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $25.54 | +80.11% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.49 | +56.66% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $3.99 | +25.31% | 3 | Mar 15, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $42 → $52 | $59.36 | -12.40% | 7 | Jan 26, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $8.05 | +61.49% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $32.79 | -14.61% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $37.44 | +38.89% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $4 | $0.59 | +580.27% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $1.07 | +2,049.53% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $3.96 | +430.30% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $5.60 | +150.00% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $18.46 | -56.66% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.64 | +2,391.05% | 2 | Dec 15, 2021 |
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $31.15
Upside: -29.37%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $77 → $74
Current: $85.64
Upside: -13.59%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $2.99
Upside: +401.67%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $25.54
Upside: +80.11%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.49
Upside: +56.66%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $3.99
Upside: +25.31%
Rhythm Pharmaceuticals
Jan 26, 2024
Maintains: Buy
Price Target: $42 → $52
Current: $59.36
Upside: -12.40%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $8.05
Upside: +61.49%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $32.79
Upside: -14.61%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $37.44
Upside: +38.89%
Aug 15, 2023
Maintains: Neutral
Price Target: $12 → $4
Current: $0.59
Upside: +580.27%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $1.07
Upside: +2,049.53%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.96
Upside: +430.30%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $5.60
Upside: +150.00%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $18.46
Upside: -56.66%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.64
Upside: +2,391.05%